Variation at the Aldosterone Synthase (CYP11B2) Locus Contributes to Hypertension in Subjects with a Raised Aldosterone-to-Renin Ratio
Pitt O. Lim,
Thomas M. Macdonald,
Christine Holloway,
Elaine Friel,
Niall H. Anderson,
Eleanor Dow,
Roland T. Jung,
Eleanor Davies,
Robert Fraser and
John M. C. Connell
Hypertension Research Centre (P.O.L., T.M.M.), Directorate of Biochemical Medicine (E.Do.), Department of Endocrinology (R.T.J.), Ninewells Hospital and Medical School, Dundee DD1 9SY, United Kingdom; Medical Research Council Blood Pressure Group (C.H., E.F., N.H.A., E.Da., R.F., J.M.C.C.), Western Infirmary, Glasgow, G11 6NT, United Kingdom; and Department of Cardiology (P.O.L.), Wales Heart Research Institute, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, United Kingdom
Abstract
The aldosterone-to-renin ratio (ARR) is a marker of aldosteroneactivity in hypertension. We examined the relationship of theARR to the distribution of two biallelic polymorphisms at theCYP11B2 gene locus. One polymorphism affects a putative steroidogenicfactor-1 binding site (-344 T/C) in the 5'-regulatory region,whereas the other marker reflects replacement of the intron-2from CYP11B2 with that from the neighboring gene encoding 11ß-hydroxylase(CYP11B1; wild-type/conversion). We studied consecutive referralsto the Tayside hypertension clinic in 1998. Because the specificityof ARR (pmol/liter/ng/ml/h) for hyperaldosteronism increaseswith its threshold, ARRs of at least 750 and 1000 were used.A total of 375 patients were assessed; 86.9% had complete data.There were significant excesses of steroidogenic factor-1 (T)(ARR 750, 0.62 vs. 0.51, P = 0.014; ARR 1000, 0.63 vs. 0.51,P = 0.039) and intron-2 (conversion) (ARR 750, 0.49 vs. 0.41,P = 0.205; ARR 1000, 0.54 vs. 0.41, P = 0.029) alleles in patientswith a raised ARR. The odds ratio for a raised ARR was 2.27[95% confidence interval, 1.01, 5.09; P < 0.05] comparingpatients with a homozygous haplotype for these alleles withthose without any such alleles, and this risk increased withage. This study supports the notion that there is a geneticcomponent that regulates aldosterone production and that hyperaldosteronismmight develop over time in susceptible individuals.
This article has been cited by other articles:
G. Escher, M. Cristiano, M. Causevic, M. Baumann, F. J. Frey, D. Surbek, and M. G. Mohaupt High aldosterone-to-renin variants of CYP11B2 and pregnancy outcome
Nephrol. Dial. Transplant.,
June 1, 2009;
24(6):
1870 - 1875.
[Abstract][Full Text][PDF]
J. M. C. Connell, S. M. MacKenzie, E. M. Freel, R. Fraser, and E. Davies A Lifetime of Aldosterone Excess: Long-Term Consequences of Altered Regulation of Aldosterone Production for Cardiovascular Function
Endocr. Rev.,
April 1, 2008;
29(2):
133 - 154.
[Abstract][Full Text][PDF]
D. A. Calhoun and N. M. Kaplan Is There an Unrecognized Epidemic of Primary Aldosteronism? (Pro)
Hypertension,
September 1, 2007;
50(3):
447 - 453.
[Full Text][PDF]
N. Iwai, K. Kajimoto, H. Tomoike, and N. Takashima Polymorphism of CYP11B2 Determines Salt Sensitivity in Japanese
Hypertension,
April 1, 2007;
49(4):
825 - 831.
[Abstract][Full Text][PDF]
M. Barr, S. M. MacKenzie, E. C. Friel, C. D. Holloway, D. M. Wilkinson, N. J.R. Brain, M. C. Ingram, R. Fraser, M. Brown, N. J. Samani, et al. Polymorphic Variation in the 11{beta}-Hydroxylase Gene Associates With Reduced 11-Hydroxylase Efficiency
Hypertension,
January 1, 2007;
49(1):
113 - 119.
[Abstract][Full Text][PDF]
D. M. McNamara, S. W. Tam, M. L. Sabolinski, P. Tobelmann, K. Janosko, A. L. Taylor, J. N. Cohn, A. M. Feldman, and M. Worcel Aldosterone Synthase Promoter Polymorphism Predicts Outcome in African Americans With Heart Failure: Results From the A-HeFT Trial
J. Am. Coll. Cardiol.,
September 19, 2006;
48(6):
1277 - 1282.
[Abstract][Full Text][PDF]
A. J Casal, V. J P Sinclair, A. M Capponi, J. Nicod, U. Huynh-Do, and P. Ferrari A novel mutation in the steroidogenic acute regulatory protein gene promoter leading to reduced promoter activity.
J. Mol. Endocrinol.,
August 1, 2006;
37(1):
71 - 80.
[Abstract][Full Text][PDF]
D. Gu, S. Su, D. Ge, S. Chen, J. Huang, B. Li, R. Chen, and B. Qiang Association Study With 33 Single-Nucleotide Polymorphisms in 11 Candidate Genes for Hypertension in Chinese
Hypertension,
June 1, 2006;
47(6):
1147 - 1154.
[Abstract][Full Text][PDF]
S. Ganapathipillai, G. Laval, I. S. Hoffmann, A. M. Castejon, J. Nicod, B. Dick, F. J. Frey, B. M. Frey, L. X. Cubeddu, and P. Ferrari CYP11B2-CYP11B1 Haplotypes Associated with Decreased 11{beta}-Hydroxylase Activity
J. Clin. Endocrinol. Metab.,
February 1, 2005;
90(2):
1220 - 1225.
[Abstract][Full Text][PDF]
B. Keavney, B. Mayosi, N. Gaukrodger, H. Imrie, M. Baker, R. Fraser, M. Ingram, H. Watkins, M. Farrall, E. Davies, et al. Genetic Variation at the Locus Encompassing 11-{beta} Hydroxylase and Aldosterone Synthase Accounts for Heritability in Cortisol Precursor (11-Deoxycortisol) Urinary Metabolite Excretion
J. Clin. Endocrinol. Metab.,
February 1, 2005;
90(2):
1072 - 1077.
[Abstract][Full Text][PDF]
O. Olivieri, A. Ciacciarelli, D. Signorelli, F. Pizzolo, P. Guarini, C. Pavan, A. Corgnati, S. Falcone, R. Corrocher, A. Micchi, et al. Aldosterone to Renin Ratio in a Primary Care Setting: The Bussolengo Study
J. Clin. Endocrinol. Metab.,
September 1, 2004;
89(9):
4221 - 4226.
[Abstract][Full Text][PDF]
E. M. Freel and J. M.C. Connell Mechanisms of Hypertension: The Expanding Role of Aldosterone
J. Am. Soc. Nephrol.,
August 1, 2004;
15(8):
1993 - 2001.
[Abstract][Full Text][PDF]
P. C. White Aldosterone: Direct Effects on and Production by the Heart
J. Clin. Endocrinol. Metab.,
June 1, 2003;
88(6):
2376 - 2383.
[Full Text][PDF]
J. Nicod, D. Bruhin, L. Auer, B. Vogt, F. J. Frey, and P. Ferrari A Biallelic Gene Polymorphism of CYP11B2 Predicts Increased Aldosterone to Renin Ratio in Selected Hypertensive Patients
J. Clin. Endocrinol. Metab.,
June 1, 2003;
88(6):
2495 - 2500.
[Abstract][Full Text][PDF]
J. M.C. Connell, R. Fraser, S. MacKenzie, and E. Davies Is Altered Adrenal Steroid Biosynthesis a Key Intermediate Phenotype in Hypertension?
Hypertension,
May 1, 2003;
41(5):
993 - 999.
[Abstract][Full Text][PDF]